Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Protagonist Therapeutics's price to book ratio was 10.4× on Nov 11, 2026, against 8.7× a year earlier. Over the last 5 years it ranged from 1.3× to 13.4×, with a median of 4.7×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 10.4× | +1.9 |
| 2025 | Dec 31, 2025 | 8.5× | +4.1 |
| 2024 | Dec 31, 2024 | 4.3× | −0.1 |
| 2023 | Dec 29, 2023 | 4.4× | +2.2 |
| 2022 | Dec 30, 2022 | 2.2× | −2.7 |
| 2021 | Dec 31, 2021 | 4.9× | +0.5 |
| 2020 | Dec 31, 2020 | 4.4× | +2.4 |
| 2019 | Dec 31, 2019 | 2.0× | +0.7 |
| 2018 | Dec 31, 2018 | 1.3× | −4.8 |
| 2017 | Dec 29, 2017 | 6.1× | +2.3 |
| 2016 | Dec 30, 2016 | 3.8× | – |
See a number that looks wrong?